肿瘤转移日渐成为肿瘤治疗的重要靶标。本研究采用肿瘤转移靶向肽(TMT)与脂质材料(PEG-DSPE)偶联获得靶向化合物(TMT-PEG-DSPE),用以构建靶向阿霉素脂质体(TMT-LS-DOX)。结果表明,TMT-LS-DOX呈现出良好的药剂学性质。选用高转移性乳腺癌细胞(MDA-MB-435S和MDA-MB-231)对该转移特异性递送系统进行评价,采用非转移性乳腺癌细胞(MCF-7)作为对照。游离TMT多肽浓度达100μg/mL时仍未显示出细胞毒性。与MCF-7相比,MDA-MB-435S及MDA-MB-231细胞对TMT-LS-DOX摄取增加,并经受体竞争性实验证明该促进作用由TMT介导。因此,TMT修饰的纳米载体可能成为增加化疗药物对高转移性乳腺癌特异性的一种新策略。
Tumor metastasis emerges as a crucial target for tumor therapy. In this study, a tumor metastasis targeting peptide(TMT) was conjugated to a lipid material(PEG-DSPE) to obtain the targeting compound(TMT-PEG-DSPE), which was used to construct the targeted liposomal doxorubicin(TMT-LS-DOX). We showed that TMT-LS-DOX presented satisfactory pharmaceutical characteristics. This metastasis-specific delivery system was tested in two highly metastatic breast cancer cell lines(MDA-MB-435S and MDA-MB-231) with a non-metastatic breast cancer cell line(MCF-7) as the control. The free TMT peptide itself showed no cytotoxicity even at the concentration of 100 μg/mL. Importantly, the enhanced cellular uptake of TMT-LS-DOX to both MDA-MB-435S and MDA-MB-231 cell lines was demonstrated as compared to MCF-7 cells, via a TMT-mediated mechanism demonstrated by a receptor competition study. In conclusion, the TMT modified nanocarriers might provide a strategy to enhance the specificity of chemotherapeutic agents to highly metastatic breast cancer.